CHINARES PHARMA has announced the successful issuance of its inaugural medium-term note series.
The company's wholly-owned subsidiary has completed the domestic issuance of the first series of 2026 medium-term notes.
The notes carry a total principal value of RMB 1.0 billion with a three-year term and an annual coupon rate set at 1.53%.
Proceeds from the issuance are designated for supplementing working capital, repaying interest-bearing debt, and other purposes compliant with applicable laws and regulations.